Top Page
ANI Pharmaceuticals
(NASDAQ:ANIP)
ANI Pharmaceuticals (ANIP) vs. SPDR S&P 500 ETF (SPY)
ANI Pharmaceuticals Business Overview & Revenue Model
ANI Pharmaceuticals Earnings Call Summary
ANI Pharmaceuticals Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 674.07M | 614.38M | 486.82M | 316.38M | 216.14M | 208.47M |
| Gross Profit | 385.28M | 364.17M | 305.30M | 177.60M | 115.53M | 121.32M |
| EBITDA | 76.14M | 79.15M | 106.60M | 48.07M | -1.68M | 29.07M |
| Net Income | -21.05M | -18.52M | 18.78M | -47.90M | -42.60M | -22.55M |
Balance Sheet | ||||||
| Total Assets | 1.29B | 1.28B | 904.42M | 760.09M | 771.60M | 461.19M |
| Cash, Cash Equivalents and Short-Term Investments | 149.80M | 151.17M | 221.12M | 48.23M | 100.30M | 7.86M |
| Total Debt | 317.53M | 624.09M | 285.67M | 286.52M | 287.37M | 185.69M |
| Total Liabilities | 848.96M | 855.17M | 446.82M | 421.55M | 412.86M | 265.49M |
| Stockholders Equity | 418.62M | 428.53M | 457.60M | 338.54M | 358.74M | 195.70M |
Cash Flow | ||||||
| Free Cash Flow | 68.37M | 47.06M | 100.45M | -47.66M | -20.32M | -53.05M |
| Operating Cash Flow | 80.74M | 64.02M | 118.96M | -31.20M | 3.32M | 15.27M |
| Investing Cash Flow | -433.50M | -404.72M | -18.51M | -15.74M | -105.48M | -68.32M |
| Financing Cash Flow | 274.76M | 264.94M | 67.44M | -5.13M | 194.59M | -1.44M |
ANI Pharmaceuticals Technical Analysis
ANI Pharmaceuticals Risk Analysis
ANI Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $1.03B | 26.46 | 19.23% | ― | 17.17% | -51.97% | |
75 Outperform | $1.45B | ― | -5.19% | ― | 30.26% | -173.36% | |
71 Outperform | $1.85B | 29.85 | 6.32% | ― | 11.82% | ― | |
68 Neutral | $1.07B | 8.21 | 19.90% | ― | 8.05% | -8.46% | |
60 Neutral | $1.03B | ― | -12.27% | ― | 3.08% | -247.82% | |
53 Neutral | $1.34B | 64.45 | -10.45% | ― | 24.76% | -783.38% | |
52 Neutral | $7.60B | 0.10 | -62.94% | 2.08% | 16.16% | 0.34% |
ANI Pharmaceuticals Corporate Events
On July 23, 2025, ANI Pharmaceuticals announced the results of the NEW DAY Study, which focused on the effectiveness of ILUVIEN for treating diabetic macular edema (DME). The study highlighted ILUVIEN’s ability to provide a constant and controlled release of fluocinolone acetonide, offering a potential alternative for patients not well served by anti-VEGF therapies. This announcement may enhance ANI Pharmaceuticals’ positioning in the ophthalmology market by addressing unmet needs in DME treatment and could potentially impact stakeholders by offering a new therapeutic option.
The most recent analyst rating on (ANIP) stock is a Buy with a $94.00 price target. To see the full list of analyst forecasts on ANI Pharmaceuticals stock, see the ANIP Stock Forecast page.
ANI Pharmaceuticals, Inc. announced the results of the NEW DAY clinical trial for ILUVIEN®, a treatment for diabetic macular edema (DME). The trial, which was presented at the American Society of Retina Specialists Annual Scientific Meeting, showed that while ILUVIEN reduced the mean number of supplemental aflibercept injections compared to the aflibercept arm, it did not meet the primary endpoint of statistical significance. However, a post-hoc analysis indicated a statistically significant reduction in supplemental injections for a subset of patients. The trial also demonstrated non-inferiority in visual acuity and anatomic changes between the ILUVIEN and aflibercept arms. These findings suggest ILUVIEN’s potential to reduce treatment burden for DME patients, although safety concerns related to increased intraocular pressure were noted.
The most recent analyst rating on (ANIP) stock is a Buy with a $94.00 price target. To see the full list of analyst forecasts on ANI Pharmaceuticals stock, see the ANIP Stock Forecast page.
ANI Pharmaceuticals has highlighted its financial performance indicators, emphasizing the importance of adjusted non-GAAP EBITDA and diluted earnings per share as measures of its operating performance. The company is addressing the impact of recent acquisitions, supply chain disruptions, and regulatory challenges on its operations, while also focusing on maintaining profitability and market acceptance of its products.
The most recent analyst rating on (ANIP) stock is a Buy with a $94.00 price target. To see the full list of analyst forecasts on ANI Pharmaceuticals stock, see the ANIP Stock Forecast page.
ANI Pharmaceuticals, Inc. held its 2025 Annual Meeting of Stockholders on May 22, 2025, where several key proposals were approved. These included amendments to the company’s stock plans and an increase in authorized shares of common stock, reflecting strategic moves to bolster its financial and operational flexibility. The meeting also saw the election of eight directors and the ratification of the appointment of EisnerAmper LLP as the independent registered public accounting firm, indicating a stable governance and financial oversight structure for the upcoming fiscal year.
The most recent analyst rating on (ANIP) stock is a Buy with a $94.00 price target. To see the full list of analyst forecasts on ANI Pharmaceuticals stock, see the ANIP Stock Forecast page.
ANI Pharmaceuticals has released a corporate presentation detailing its financial performance and strategic initiatives as of May 2025. The company emphasizes the importance of adjusted non-GAAP financial measures, such as EBITDA and diluted earnings per share, as key indicators of its operating performance. These metrics exclude various non-cash and one-time expenses to provide a clearer picture of the company’s financial health. The presentation also highlights potential risks and uncertainties, including supply chain disruptions and regulatory challenges, which could impact its operations and financial results.
The most recent analyst rating on (ANIP) stock is a Buy with a $94.00 price target. To see the full list of analyst forecasts on ANI Pharmaceuticals stock, see the ANIP Stock Forecast page.
On April 10, 2025, ANI Pharmaceuticals filed a definitive proxy statement for its 2025 annual meeting of shareholders to consider several proposals, including the approval of the Amended and Restated 2022 Stock Incentive Plan. The company issued a Proxy Supplement to clarify that non-shareholder approved inducement grants are included in the share reserve increase proposal. As of March 24, 2025, ANI Pharmaceuticals had 1,177,800 shares available for future grants under the Stock Plan, which is deemed insufficient to attract and retain key talent. The company emphasizes the importance of the Stock Plan in its compensation strategy, aligning with market standards to motivate and retain employees.